Mayo Clinic doctors have many treatments for hepatitis C, an infection caused by a virus that attacks your liver. If hepatitis causes severe damage to your liver, you may need a liver transplant. In addition, you may need to take medications to prevent the condition from returning after your transplant.
Mayo Clinic doctors study which immunosuppressive medications may be most appropriate for people with hepatitis C who have had liver transplants, and which medications may reduce the chances of hepatitis C returning. They also study the use of antiviral therapy before or after liver transplant for some people with hepatitis C. In addition, researchers are studying which donor or recipient risk factors may affect the chance of hepatitis C recurring.
Jan. 17, 2018
References
- Scientific Registry of Transplant Recipients. http://www.srtr.org/default.aspx. April 11, 2016.
- U.S. News & World Report. U.S. News Best Hospitals 2015-16. http://health.usnews.com/best-hospitals/rankings. Accessed Feb. 22, 2016.
- Barbara Woodward Lips Patient Education Center. Liver transplant. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2013.
- Eggebraaten KR (expert opinion). Mayo Clinic, Rochester, Minn. May 23, 2016.
- Barbara DW, et al. The perioperative management of patients undergoing combined heart-liver transplantation. Transplantation. 2015;99:139.
- Bulatao IG, et al. Avoiding stay in the intensive care unit after liver transplantation: A score to assign location of care. American Journal of Transplantation. 2014;14:2088.
- Heimbach JK (expert opinion). Mayo Clinic, Rochester, Minn. June 28, 2016.
- Stulak JM, et al. Combined heart and abdominal organ transplantation: Excellent outcomes gained from a unique experience. Journal of Heart and Lung Transplantation. 2014;33:S278.
- Ibrahim SH (expert opinion). Mayo Clinic, Rochester, Minn. June 14, 2016.
- Glorioso JM, et al. Pivotal preclinical trial of the spheroid reservoir bioartificial liver. Journal of Hepatology. 2015;63:388.
- Heimbach JK, et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. American Journal of Transplantation. 2013;13:363.
- Murad SD, et al. Long-term clinical and radiological follow up of living liver donors. Liver Transplantation. In press. Accessed May 11, 2016.
- Murad SD, et al. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology. 2012;56:973.
- Barbara Woodward Lips Patient Education Center. About your child's liver transplant. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2009.
- Rizvi S, et al. Primary sclerosing cholangitis as a premalignant biliary tract disease: Surveillance and management. Clinical Gastroenterology and Hepatology. 2015;13:2152.
- Taner T, et al. Decreased chronic cellular and antibody-mediated injury in the kidney following simultaneous liver-kidney transplantation. Kidney International. 2016;89:909.
- Watt KD, et al. A practical guide to the management of HCV infection following liver transplantation. American Journal of Transplantation. 2009;9:1707.
- Rosen CB, et al. Liver transplantation for cholangiocarcinoma. Transplant International. 2010;23:692.
- Raichlin E, et al. Combined heart and liver transplantation: A single-center experience. Transplantation. 2009;88:219.
- Nagourney E. 'Domino' transplants: Rare and risky. The New York Times. http://www.nytimes.com/2000/05/02/health/domino-transplants-rare-and-risky.html. Accessed May 12, 2016.
- Kitchens WH. Domino liver transplantation: Indications, techniques, and outcomes. Transplantation Reviews. 2011;25:167.
- Yu Y, et al. Cell therapies for liver diseases. Liver Transplantation. 2012;18:9.
- Croome KP, et al. The use of donation after cardiac death allografts does not increase recurrence of hepatocellular carcinoma. American Journal of Transplantation. 2015;15:2704.
- De Assuncao TM, et al. Development and characterization of human-induced pluripotent stem cell-derived cholangiocytes. Laboratory Investigation. 2015;95:684.
- Riggin EA. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Feb. 15, 2016.
- Brown AY. Allscripts EPSi. Mayo Clinic, Rochester, Minn. March 22, 2016.
- Cook AJ. Allscripts EPSi. Mayo Clinic, Rochester, Minn. May 2, 2014.
- Krowka MJ, et al. International Liver Transplant Society practice guidelines: Diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension. Transplantation. 2016;100:1440.
- Patel K, et al. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus. World Journal of Gastroenterology. 2011;17:4581.
- Singh S, et al. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: A diagnostic accuracy systematic review and individual participant data pooled analysis. European Radiology. 2016;26:1431.
- Han L, et al. Extracorporeal liver support and liver transplant for patients with acute-on-chronic liver failure. Seminars in Liver Disease. 2016;36:153. https://www.thieme-connect.de/products/ejournals/html/10.1055/s-0036-1583197. Accessed June 29, 2016.
- Gallagher C. Transplant genomics enters collaboration with Mayo Clinic (news release). Mayo Clinic, Rochester, Minn. June 27, 2016.
- Heilman RL (expert opinion). Mayo Clinic, Phoenix/Scottsdale, Ariz. June 24, 2016.